

## Association between ankylosing spondylitis and venous thromboembolism

Ankylosing spondylitis is a type of arthritis that commonly affects the joints of the spine. The relationship between ankylosing spondylitis and other diseases has been extensively explored.<sup>1,2</sup> Recently, a cohort study in Canada conducted by Aviña-Zubieta *et al* published in *Annals of Rheumatic Diseases* disclosed that people with ankylosing spondylitis were at higher risk of venous thromboembolism compared with people without ankylosing spondylitis (HR 1.53, 95% CI 1.16 to 2.01).<sup>3</sup> Aviña-Zubieta *et al*'s study is well performed and is informative to the researchers. Some of my views are shared with the readers as follows. First, the overall incidence of venous thromboembolism was 2.03-fold higher in people with ankylosing spondylitis than in those people without ankylosing spondylitis in Aviña-Zubieta *et al*'s study (1.56 vs 0.77 per 1000 person-years).<sup>3</sup> The attributable risk associated with ankylosing spondylitis was 0.79 per 1000 person-years; that is, removal of ankylosing spondylitis can diminish approximately eight cases of venous thromboembolism per 10 000 person-years of follow-up. Second, another cohort study in the Republic of Korea disclosed that the overall incidence of new onset of atrial fibrillation was 1.54-fold higher in people with ankylosing spondylitis than in those without ankylosing spondylitis (2.32 vs 1.51 per 1000 person-years).<sup>4</sup> The attributable risk associated with ankylosing spondylitis was 0.81 per 1000 person-years; that is, removal of ankylosing spondylitis can diminish approximately eight cases of new onset of atrial fibrillation per 10 000 person-years of follow-up. According to the above measurement, ankylosing spondylitis seems to have a similar impact on the risks of venous thromboembolism and new onset of atrial fibrillation. Third, the evidence disclosed that people with ankylosing spondylitis who underwent tumour necrosis factor inhibitor therapy had a higher risk of new onset of atrial fibrillation (HR 1.60, 95% CI 1.02 to 2.39),<sup>4</sup> but Aviña-Zubieta *et al*'s study did not disclose such data. I agree with Aviña-Zubieta *et al*'s comments that future investigation is needed to clarify the effects of ankylosing spondylitis treatment on the risk of venous thromboembolism. Fourth, ankylosing spondylitis cannot be prevented and is less likely to be eradicated. Currently, the guidelines for stroke prevention in people with atrial fibrillation have been established.<sup>5</sup> In addition, it is important to recognise people who have risk factors for venous thromboembolism, including those having cancer, major surgery, major trauma-like fractures and long-term immobilisation.<sup>6</sup> Clinicians who participate in the long-time care of people with ankylosing spondylitis should take into consideration the above risk factors when considering the risk of venous

thromboembolism. If necessary, pharmacological prophylaxis for venous thromboembolism should be initiated in these high-risk people.

Shih-Wei Lai  <sup>1,2</sup>

<sup>1</sup>Department of Public Health, College of Public Health and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan

<sup>2</sup>Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan

**Correspondence to** Dr Shih-Wei Lai, Department of Family Medicine, China Medical University Hospital, Taichung 404, Taiwan; wei@mail.cmuh.org.tw

**Correction notice** This article has been corrected since it published Online First. The first affiliation has been updated.

**Handling editor** Josef S Smolen

**Contributors** S-WL contributed to the conception of the article, initiated the draft of the article and approved the final draft submitted.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Not necessary

**Provenance and peer review** Not commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.



**To cite** Lai S-W. *Ann Rheum Dis* Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2019-215854

Received 7 June 2019

Accepted 8 June 2019

*Ann Rheum Dis* 2019;0:1. doi:10.1136/annrheumdis-2019-215854

**ORCID iD**

Shih-Wei Lai <http://orcid.org/0000-0002-7420-1572>

### REFERENCES

- Chen H-H, Yeh S-Y, Chen H-Y, *et al*. Ankylosing spondylitis and other inflammatory spondyloarthritis increase the risk of developing type 2 diabetes in an Asian population. *Rheumatol Int* 2014;34:265–70.
- Sun L-M, Muo C-H, Liang J-A, *et al*. Increased risk of cancer for patients with ankylosing spondylitis: a nationwide population-based retrospective cohort study. *Scand J Rheumatol* 2014;43:301–6.
- Aviña-Zubieta JA, Chan J, De Vera M, *et al*. Risk of venous thromboembolism in ankylosing spondylitis: a general population-based study. *Ann Rheum Dis* 2019;78:480–5.
- Moon I, Choi E-K, Jung J-H, *et al*. Ankylosing spondylitis: A novel risk factor for atrial fibrillation - A nationwide population-based study. *Int J Cardiol* 2019;275:77–82.
- Proietti M, Lane DA, Boriani G, *et al*. Stroke prevention, evaluation of bleeding risk, and anticoagulant treatment management in atrial fibrillation contemporary international guidelines. *Can J Cardiol* 2019;35:619–33.
- Goldhaber SZ. Risk factors for venous thromboembolism. *J Am Coll Cardiol* 2010;56:1–7.

## Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting [http://www.adobe.com/go/reader\\_download](http://www.adobe.com/go/reader_download).

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.